During the study, participants will wear heart monitoring patches that record their heart rhythm to measure how much time they spend in atrial fibrillation. The study will also look at how safe the medication is by checking for any unwanted effects, measuring vital signs like blood pressure and heart rate, and doing blood tests. The researchers will also measure the amount of medication in the blood at different times to understand how the body processes it. Participants need to be in normal heart rhythm at the start of the study, which means those with persistent atrial fibrillation will need to have their heart rhythm corrected before joining.

The study will track when participants experience episodes of atrial fibrillation using various monitoring methods including the heart patches, standard heart tracings, and handheld devices. Participants will already need to be taking medication to prevent stroke, as recommended by medical guidelines for people with atrial fibrillation. The study will continue for several months to gather enough information about how well the medication works and whether it is safe for people with this heart condition.

The research involves checking how well the medicine works to prevent LEAF, which refers to long, continuous episodes of irregular heart rhythms lasting five hours or more. During the study, participants will be monitored for adverse events, which are any unexpected or harmful medical occurrences that happen during treatment. This includes watching for major adverse cardiac events, such as a stroke or issues related to sudden heart rhythm changes. Regular checks of vital signs, like blood pressure and heart rate, as well as laboratory assessments to monitor organ functions like the thyroid, will be conducted throughout the process.

Participants in this study will be assigned to receive either the inhaled gas or a placebo. The process involves monitoring the heart rhythm and the overall well-being of individuals for a period of three months to see if the treatment helps reduce the recurrence of the irregular heartbeat and improves how patients feel in their daily lives.

The purpose of this study is to find out if treatment with semaglutide can help patients stay free from irregular heart rhythms after having catheter ablation, compared to receiving standard care without this medication. The study will look at whether patients remain free from atrial fibrillation, atrial flutter, or atrial tachycardia (different types of irregular heart rhythms) lasting 30 seconds or longer during the 12 months following the ablation procedure. The study will not count any irregular heart rhythms that happen during the first 3 months after the procedure, as this is considered a normal recovery period.

During the study, patients will have their heart rhythm continuously monitored using a small device called an implantable loop recorder, which is placed under the skin to track the heart’s activity over time. The treatment with semaglutide will be given for a period of up to 18 months, and the total study is expected to last several years. Women who could become pregnant will need to use effective birth control methods during the study and will have pregnancy tests to ensure they are not pregnant before starting.

The purpose of this research is to evaluate how well Etacizin works in maintaining normal heart rhythm in patients with atrial fibrillation compared to Propafenone over a six-month period. The study is open-label, which means both patients and doctors will know which medication is being used during treatment.

During the study, participants will receive either Etacizin (up to 200 mg daily) or Propafenone (up to 900 mg daily) for approximately seven months. The research will monitor how well these medications prevent the return of irregular heart rhythm after normal heart rhythm has been restored. The study will also track other important factors such as quality of life and heart-related health events during the treatment period.

The treatment involves taking AP31969 tablets orally for a period of 12 weeks. The medication will be provided as film-coated tablets in various dosage strengths. Some participants will receive the active medication, while others will receive placebo tablets that look identical to the real medication but contain no active substance.

During the study, participants will have their heart rhythm monitored continuously through special recording devices. The study will track how often atrial fibrillation episodes occur and how long they last. Participants will also complete questionnaires about their quality of life and symptoms related to their heart condition.

The study will use several heart rhythm control medications including dronedarone hydrochloride, propafenone hydrochloride, amiodarone hydrochloride, and flecainide acetate. These medications are taken by mouth in tablet form and work to help regulate the heart’s rhythm. The maximum daily doses range from 300 to 800 milligrams, depending on the specific medication used.

During the study, patients will be monitored for various heart and blood vessel-related health events, including additional strokes, heart problems requiring hospitalization, and changes in heart function. The study will also track patients’ overall well-being, including their ability to perform daily activities, quality of life, and mental function. Participants will be followed for up to 24 months after starting treatment.

The research focuses on frail older patients over 70 years of age who are taking DOACs. Frailty is a condition characterized by reduced strength, endurance, and physiological function that increases vulnerability to health problems. The study will measure the levels of DOACs in participants’ blood and make adjustments to their medication dosage when necessary.

The researchers will track whether this strategy reduces complications such as bleeding events or thromboembolic events (blood clots that can travel through the bloodstream). Ischemic stroke (when a blood vessel supplying blood to the brain is blocked), transient ischemic accident (TIA) (a temporary period of symptoms similar to a stroke), and peripheral thromboembolism (blood clots in vessels away from the heart and brain) will be monitored as part of the study.

The purpose of this study is to understand how the body processes and responds to amiodarone when given in these two different ways. This involves measuring the levels of amiodarone and its active component, N-desethylamiodarone, in the blood, as well as in samples from the lungs and breath. The study will involve patients who are in the intensive care unit and are receiving mechanical ventilation, which is a machine that helps them breathe.

Participants in the study will receive either the standard intravenous form of amiodarone or the enteral form as part of their treatment for atrial fibrillation. The study will last for a maximum of seven days, during which the effects of the medication will be closely monitored. This research aims to provide valuable insights into the best way to administer amiodarone to critically ill patients with atrial fibrillation, potentially improving treatment outcomes for this condition.

The medications being studied include Edoxaban, Apixaban, Warfarin, Dabigatran Etexilate, and Rivaroxaban. These are all oral anticoagulants, which means they are taken by mouth to help prevent blood clots. The purpose of the study is to understand the overall effects of these medications when resumed at different times after surgery, focusing on events like stroke, bleeding, and death related to blood vessels.

Participants in the study will be randomly assigned to either restart their anticoagulation medication early or later after their surgery. The study will monitor various health outcomes over a period of time to determine the best approach for managing anticoagulation in these patients. The trial aims to provide valuable information that could help improve treatment strategies for individuals with both chronic subdural hematoma and atrial fibrillation.

The purpose of the study is to compare the ability of a standard dose (200 mg per day) and a reduced dose (100 mg per day) of amiodarone hydrochloride to maintain a normal heart rhythm for 12 months after cardioversion in patients with persistent atrial fibrillation. Participants in the study will be randomly assigned to receive either the standard dose or the reduced dose of the medication. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient.

Throughout the study, participants will be monitored for any recurrence of irregular heartbeats and for any side effects that may occur. The study will also look at how the body processes the medication and whether genetic factors affect its effectiveness and safety. The trial is expected to continue until June 2028, with recruitment starting in November 2024.

The purpose of the study is to determine if flecainide is better than amiodarone in helping patients return to a normal heart rhythm. Participants will receive either flecainide or amiodarone through an injection. The study will monitor how well each medication works in restoring normal heart rhythm and how safe they are for the patients. The effects of the medications will be observed for up to 24 hours, with particular attention to any side effects or complications that may arise.

Throughout the study, the frequency of successful heart rhythm conversion and any side effects will be recorded. The trial aims to provide valuable information on the effectiveness and safety of these medications in treating paroxysmal atrial fibrillation in patients with coronary artery disease. This research could help improve treatment options for individuals experiencing this heart condition.

The study tests whether allopurinol, a medication that lowers uric acid levels in the blood, can help reduce the risk of cardiovascular events. Some participants will receive allopurinol tablets, while others will receive a placebo. The treatment will continue for approximately 5 years, during which participants will have regular check-ups to monitor their health status.

The main focus is to determine if allopurinol can prevent serious cardiovascular events such as heart problems, strokes, or the need for heart-related procedures. The study will also track other health changes, including heart function, blood vessel health, and the presence of long-COVID symptoms. Regular blood tests and heart examinations will be performed to monitor participants’ health throughout the study period.

The purpose of this research is to determine the safest and most effective way to use these blood-thinning medications after the closure procedure. The study compares different durations of treatment: some patients will take both medications for 30 days and then continue with just one medication for 6 months, while others will take both medications for the full 6 months.

The medications are taken by mouth once daily, with each tablet containing 75 mg of either acetylsalicylic acid or clopidogrel. The study will monitor patients for any heart-related events and bleeding complications to determine which treatment approach provides the best balance of preventing blood clots while minimizing bleeding risks.

The medications being studied in this trial include Dabigatran Etexilate, Apixaban, Rivaroxaban, Edoxaban, Clopidogrel, and Aspirin. These medications are taken orally, meaning they are swallowed in the form of tablets or capsules. The trial will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications. The purpose of the study is to see which treatment is more effective in preventing device-related blood clots after the LAAC procedure.

Participants in the study will be monitored over a period of time to observe the occurrence of any blood clots or other related health events. The study will last for about eight weeks, during which the participants will receive one of the treatments. After this period, the participants will be checked for any signs of blood clots using medical imaging techniques like computed tomography or transesophageal echocardiography (TEE), which is a type of ultrasound that provides images of the heart. The study will also track any other health events such as strokes or bleeding incidents over a longer period to ensure the safety and effectiveness of the treatments.

The purpose of the study is to determine if using an implantable device to monitor heart activity and guide anticoagulant treatment is safer in terms of reducing bleeding events compared to the standard approach. The study will involve the use of a small device placed inside the body that can send heart activity data to doctors remotely. This will help in deciding the best way to manage the anticoagulant treatment.

Participants in the study will be monitored over a period of two years. During this time, the occurrence of any bleeding events and other heart-related events will be recorded. The study aims to provide insights into whether this new method of monitoring and treatment can improve safety and outcomes for patients with these heart conditions.

Participants in the study will be randomly assigned to receive either edoxaban or a placebo, which is a pill that looks like the medication but does not contain any active ingredients. The study will last for a period of 12 weeks, during which participants will take their assigned tablets daily. Throughout the study, participants will be monitored for any signs of stroke, blood clots, or bleeding events. The goal is to see if edoxaban is effective and safe for people with atrial fibrillation who have had a previous intracranial hemorrhage.

By participating in this study, researchers hope to gather important information that could help improve treatment options for patients with atrial fibrillation and a history of brain bleeding. The findings may lead to better ways to prevent strokes and other complications in this high-risk group of patients. The study is expected to be completed by April 2026.

The study will test two blood-thinning medications: acetylsalicylic acid (commonly known as aspirin) and clopidogrel. These medications help prevent blood clots from forming. Both medications are taken as tablets by mouth. The study will compare different durations of taking these medications, including using both medications together for different periods versus using just one medication.

Patients who participate will be monitored for several important health outcomes, including stroke, blood clots, bleeding events, and heart-related complications. The study will also look at brain function using MRI scans and cognitive tests to ensure the treatment approach is safe and effective. The medications will be given in specific doses – 75 mg daily for each medication – and patients will be followed for several months to evaluate the safety and effectiveness of different medication combinations.

The study uses two medications: Heparin, which is a blood-thinning medication given by injection, and physiological saline solution, which is a sterile salt water solution used during medical procedures. The main purpose is to determine when it is safest and most effective to start blood-thinning treatment in patients undergoing these heart procedures.

During the study, patients will receive either standard timing of blood-thinning medication or a different timing schedule. The effects will be monitored through various medical examinations, including imaging of the heart and brain, to ensure patient safety and evaluate the effectiveness of different timing approaches. The study will track any complications or adverse events that might occur during and after the procedures.

The study involves several medications, including Eliquis (apixaban), Xarelto (rivaroxaban), Pradaxa (dabigatran etexilate), Lixiana (edoxaban), Brilique (ticagrelor, also known as AZD6140), Clopidogrel, Marcumar (phenprocoumon), and Aspirin (acetylsalicylic acid). Some participants will receive these medications, while others may receive a placebo. The trial will last for a period of 90 days, during which participants will take the medications orally in the form of tablets or capsules.

The purpose of the study is to determine if adding these anticoagulant medications can effectively prevent thromboembolic events, such as blood clots, while also monitoring for any major bleeding risks. Participants will be observed for any occurrences of death, stroke, heart attack, or other related conditions. The study will also assess the overall clinical benefits and any potential side effects of the treatment over a period of 180 days after the initial randomization. This research is important for improving the management of atrial fibrillation in patients who have recently undergone heart surgery.

The purpose of the study is to assess the safety and effectiveness of this treatment approach compared to the current standard treatment, which involves using a combination of medications to prevent blood clots. The study will follow patients for a period of 15 months to monitor for any major heart or brain events, such as heart attacks or strokes, as well as any significant bleeding events. The trial will also compare the outcomes of using the P2Y12 inhibitor alone for one month, followed by the DOAC alone for a longer period, against the standard treatment that involves multiple medications over several months.

Participants in the study will receive either the new treatment approach or the standard treatment. The study will help determine if the new approach is as safe and effective as the current standard. This research is important for improving treatment options for patients with atrial fibrillation who have undergone PCI, potentially leading to better health outcomes and fewer complications.

The purpose of the study is to determine if treatment with dapagliflozin can extend the time before atrial fibrillation returns within 30 days after a procedure called cardioversion. Cardioversion is a medical procedure used to restore a normal heart rhythm in people with certain types of abnormal heartbeats. Participants in the study will be randomly assigned to receive either dapagliflozin or the usual care. The study will monitor the recurrence of atrial fibrillation and other related outcomes over a period of 30 days following cardioversion.

Throughout the study, researchers will observe various factors, such as the proportion of patients who maintain a normal heart rhythm 30 days after cardioversion and the total number of days with atrial fibrillation recordings during this period. The study aims to provide valuable insights into whether dapagliflozin can be an effective treatment option for managing atrial fibrillation after cardioversion.

The purpose of the study is to compare two different treatment plans using amiodarone. One group of patients will take the medication for one month, while another group will take it for five days before undergoing electrical cardioversion. The study will observe how effective amiodarone is in helping the heart return to a normal rhythm and how long this normal rhythm is maintained after the procedure.

Participants in the study will be monitored to see how quickly their heart rhythm returns to normal after starting amiodarone and whether the normal rhythm is maintained during the month following the electrical cardioversion. The study will provide valuable information on the best way to use amiodarone for patients with persistent atrial fibrillation, which is when the irregular heart rhythm lasts for seven days or more.

The purpose of the study is to evaluate how well these treatments work in preventing new ischemic lesions in the brain, which are areas of tissue damage caused by a lack of blood flow. These lesions will be monitored using MRI scans of the brain, taken within 24 hours after the procedure and again after three months. The study will also look at other outcomes, such as any new symptoms of stroke or bleeding events, and assess the overall health and cognitive function of the participants over the three-month period.

Participants in the study will be monitored closely, with regular check-ups and assessments to ensure their safety and to gather data on the effectiveness of the treatments. The trial aims to provide valuable information on the best strategy for preventing complications in patients with atrial fibrillation who have undergone LAAC, ultimately helping to improve patient care and outcomes.

The purpose of the study is to determine which treatment is more effective in restoring normal heart rhythm in patients who have experienced AF for less than 48 hours. Participants in the study will receive either the combination of flecainide and ranolazine or flecainide alone. The study will monitor how quickly and effectively each treatment restores normal heart rhythm.

Participants will be observed to see how many of them return to a normal heart rhythm within three hours and six hours after starting the treatment. The study will help to understand if adding ranolazine to flecainide provides any additional benefit in treating recent onset AF compared to using flecainide alone. This information could be valuable in improving treatment strategies for patients with this heart condition.

The purpose of the study is to determine if using just one medication is as effective as using both medications together in preventing complications such as blood clots, bleeding, or death within six months after the procedure. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of six months to observe any differences in outcomes between the two groups.

Throughout the study, participants will have regular follow-up visits to check their health and any side effects from the medications. The study will help doctors understand the best way to manage patients with atrial fibrillation who have undergone the left atrial appendage closure procedure, aiming to improve patient care and outcomes.

The purpose of the study is to see if Teprenone can reduce the chances of developing atrial fibrillation after undergoing heart surgery, such as surgery for mitral or aortic valve issues or coronary artery disease. Participants in the study will receive either the medication or a placebo, and their heart rhythm will be monitored to check for any signs of atrial fibrillation. The study will also look at how the medication affects certain proteins in the body that help protect cells from stress.

The study will take place over a period of time, with participants being monitored closely after their surgery. The researchers will use various methods to assess the effects of the medication, including checking heart rhythms and analyzing blood and tissue samples. The goal is to gather information that could lead to better prevention strategies for atrial fibrillation after heart surgery.

The purpose of this research is to determine how well rivaroxaban works and how safe it is when used long-term in preventing strokes and blood clots, compared to usual care methods. The study will also monitor for any major bleeding events that might occur during treatment. Participants will take either rivaroxaban tablets or receive standard care treatment for a period of 24 months.

During the study, patients will undergo regular check-ups and will have MRI (magnetic resonance imaging) scans of their brain at the beginning and end of the study. The research will track any occurrences of stroke or blood clots, as well as monitor for bleeding complications. Patients will also have their heart rhythm checked using Holter ECG monitoring (a portable device that records heart activity) at various points during the study.

The purpose of the study is to determine whether continuing long-term treatment with rivaroxaban is better than using acetylsalicylic acid alone in preventing strokes and other similar events in patients who are at moderate risk after their successful catheter ablation. Participants in the study will be randomly assigned to receive either rivaroxaban or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 36 months, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment.

The main goal is to see if there is a difference in the occurrence of strokes or other related events between the two treatment groups. The study will also look at other outcomes, such as the occurrence of bleeding, changes in brain scans using MRI, and overall quality of life. This information will help doctors understand the best way to prevent strokes in patients who have had atrial fibrillation and have undergone catheter ablation.

The purpose of the study is to compare the effects of these NOACs with no anticoagulation treatment on preventing certain health issues. These issues include non-hemorrhagic stroke, which is a type of stroke not caused by bleeding in the brain, and systemic embolism, which is when a blood clot travels through the bloodstream and causes blockages. The study also looks at vascular mortality, which refers to deaths related to blood vessel problems, and other conditions like heart attacks and blood clots in the veins.

Participants in the study will be randomly assigned to receive either one of the NOACs or no anticoagulation treatment. The study will last for a period of up to 120 days, during which the health of the participants will be monitored to see how well the medications work in preventing the mentioned health issues. The goal is to gather information that could help improve treatment options for patients who experience atrial fibrillation after surgery.

The purpose of the study is to evaluate the effect of Abelacimab compared to Rivaroxaban on the rate of major or clinically relevant non-major bleeding events. Participants in the study will receive either Abelacimab or Rivaroxaban and will be monitored over a period of time to observe any bleeding events that occur. The study will help determine which treatment is safer and better tolerated for patients with atrial fibrillation.

Throughout the study, participants will be closely observed to track the time to the first occurrence of major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH). The study will also look at the time to the first occurrence of major or minor bleeding events. This information will help healthcare professionals understand the safety profile of Abelacimab compared to Rivaroxaban in managing atrial fibrillation.